Drugs / DN1406131
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03641794 | Sep 2018 → May 2019 | cancer | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DN1406131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03641794 ↗ |
| Action | Inhibit | “IDO1 and TDO2 inhibitor” NCT03641794 ↗ |
| Route | Oral | “escalating oral doses” NCT03641794 ↗ |